BLAINJECTIONINJECTABLEPriority Review
Approved
Nov 2022
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
TZIELD (teplizumab-mzwv) by Sanofi is cd3-directed antibody interactions [moa]. First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TZIELD is a CD3-directed monoclonal antibody approved by the FDA in November 2022 for delaying the onset of clinical type 1 diabetes in at-risk individuals. It works by modulating CD3-expressing T cells to preserve insulin-producing beta cell function. This represents a first-in-class approach to disease prevention rather than treatment after diagnosis.
Peak
Early-stage peak-phase asset in a specialized indication with moderate competitive pressure (30); commercial team is building out infrastructure for a niche patient population.
Mechanism of Action
CD3-directed Antibody Interactions
Pharmacologic Class:
CD3-directed Antibody
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
Sanofi is hiring 10 roles related to this product
Worked on TZIELD at Sanofi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.